INmune Bio Co-Founder and CEO Presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019
LA JOLLA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB ), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that R.J. Tesi, M.D., the company’s co-founder and CEO, presented at the Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019 on March 18 in London. In his presentation, Dr. Tesi addressed how combination therapy with INmune Bio’s drug candidate INB03 can help target myeloid-derived suppressor cells (MDSC) to reverse resistance to checkpoint inhibitors.
“I am excited to have the opportunity to present and exchange ideas with some of the most influential members of the immuno-oncology community,” said Dr. Tesi. “We are committed to developing treatments that target the patient’s innate immune system and facilitating an understanding that chronic inflammation is a root cause and agitator of cancer and many other diseases. By exchanging ideas with top researchers, we can help further push developments that lead to effective patient responses at the bedside.”
Dr. Tesi’s presentation is titled “ Targeting Myeloid-Derived Suppressor Cells to Overcome Resistance to Checkpoint Inhibitors,” in which he delved into how the number of MDSC in a patient’s blood is a predictor of resistance to checkpoint inhibitors. INB03, a second-generation tumor necrosis factor (TNF) inhibitor currently being tested in a Phase 1 clinical trial, targets soluble TNF to decrease MDSC while improving natural killer-dendritic cells crosstalk and cytotoxic T cell recruitment to the tumor. By protecting transmembrane TNF function, INB03 does not cause immunosuppression, a known off-target effect of currently approved non-selective TNF inhibitors.
Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit brings together leaders from across the immunotherapy industry, connecting scientists, researchers, analysts and investors to facilitate the exchange of ideas and developments. Immunology-related drug targets are discussed to address the latest discoveries in the field.
About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this prospectus, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this prospectus relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.
INmune Bio Contact: David Moss, CFO(858) 964-3720 DMoss@INmuneBio.com
Media Contact: Antenna GroupSharon Golubchik(201) 465-8008 INmuneBio@AntennaGroup.com
Investor Contact: KCSA Strategic CommunicationsValter Pinto / Scott Eckstein PH: (212) 896-1254 / (212) 896-1210 INmune@KCSA.com